Ongoing or re-emerging subjective insomnia symptoms after full/partial remission or recovery of major depressive disorder mainly with the selective serotonin reuptake inhibitors and risk of relapse or recurrence: A 52-week follow-up study

Abstract Background Many patients who remit fully/partially or recover from an episode of major depression continue to suffer from sleep problems, mainly insomnia. Our study assesses the frequency and types of ongoing or re-emerging subjective insomnia symptoms and their relationship to subsequent d...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of affective disorders 2011-11, Vol.134 (1), p.257-265
Hauptverfasser: Gulec, Mustafa, Selvi, Yavuz, Boysan, Murat, Aydin, Adem, Besiroglu, Lutfullah, Agargun, Mehmet Yucel
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 265
container_issue 1
container_start_page 257
container_title Journal of affective disorders
container_volume 134
creator Gulec, Mustafa
Selvi, Yavuz
Boysan, Murat
Aydin, Adem
Besiroglu, Lutfullah
Agargun, Mehmet Yucel
description Abstract Background Many patients who remit fully/partially or recover from an episode of major depression continue to suffer from sleep problems, mainly insomnia. Our study assesses the frequency and types of ongoing or re-emerging subjective insomnia symptoms and their relationship to subsequent depressive relapse or recurrence in a group of full/partial remitters or recoverers. Method Sixty patients, 18 to 65 years of age, with current MDD defined using DSM-IV-TR criteria were participated in the study. They began a 24-week course of open-label acute plus continuation phase treatment mainly with SSRIs. Maintenance treatment was not planned for not affecting natural relapse or recurrence rates. All participants were evaluated by CGI-S, BDI, HAMD-17, PSQI, and ISI at weeks 0, 4, 12, 24, and 52. Results Majority of the participants (83.33%) had subjective sleep disturbance, insomnia prior to relapse or recurrence. Repeated measures ANOVA was used to evaluate changes in scores of depression and sleep scales over time between recurred (N = 12) and non-recurred groups (N = 48). Differences between means were calculated with post hoc Bonferroni comparison test. The changes in scores of entire clinical scales over time between recurred and non-recurred groups were statistically significant. Limitations The limitations of this study include the use of a relatively small, mostly young female sample and the lack of an objective sleep measure to corroborate self-report scales. Conclusions Early recognition and treatment of disturbances of the sleep–wake cycle may be important for treatment and prevention of recurrence of depression.
doi_str_mv 10.1016/j.jad.2011.05.056
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_888340946</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165032711003181</els_id><sourcerecordid>1010708558</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-651f8570d5da120f5e364b17e0d90303bec2cdca30a358171d49f1e676e6c0e3</originalsourceid><addsrcrecordid>eNp9kl-L1DAUxYso7rr6AXyRvIi-dPambdqOgrAs_oOFfXDfQya5nUknTWqSztAv7WcwZUYFHxYCIe3vnBNObpa9prCiQOvrftULtSqA0hWwtOon2SVlTZkXjDZPs8vEsBzKornIXoTQA0C9buB5dlHQuq2S7DL7dW-3TtstcZ54zHFAv12OYdr0KKM-INE2uMFqQcI8jNENgYguoifdZMz1KHzUwiTtoEPQzp6MpDugn4nryCD69EXh6DH9T3ZKB-dV0g9CWzOTo447EndIAppzYkDvorPaJqdpjGK_XGKnNzo6n9KtIl6H_eLu0Ygx4Dl08h6txA_khrAiPyLuSeeMccd8GkmIk5pfZs86YQK-Ou9X2cOXzw-33_K7-6_fb2_uclk1EPOa0a5lDSimBC2gY1jW1YY2CGoNJZQblIVUUpQgStbShqpq3VGsmxprCVheZe9OtqN3PycMkad2JBojLLop8LZtywrWVZ3I94-S6Z2hgZaxNqH0hErvQvDY8dHrQfg5QQtX856neeDLPHBgaS32b87202ZA9VfxZwAS8PYMiCCF6bywUod_XJVaqNZL-McTh6m1g0bPg9RL2Uqn4iNXTj96jU__qaXRVqfAPc4Yejd5m56DUx4KDvzHMrjL3FIKUNKWlr8BdH_t2w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1010708558</pqid></control><display><type>article</type><title>Ongoing or re-emerging subjective insomnia symptoms after full/partial remission or recovery of major depressive disorder mainly with the selective serotonin reuptake inhibitors and risk of relapse or recurrence: A 52-week follow-up study</title><source>MEDLINE</source><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Gulec, Mustafa ; Selvi, Yavuz ; Boysan, Murat ; Aydin, Adem ; Besiroglu, Lutfullah ; Agargun, Mehmet Yucel</creator><creatorcontrib>Gulec, Mustafa ; Selvi, Yavuz ; Boysan, Murat ; Aydin, Adem ; Besiroglu, Lutfullah ; Agargun, Mehmet Yucel</creatorcontrib><description>Abstract Background Many patients who remit fully/partially or recover from an episode of major depression continue to suffer from sleep problems, mainly insomnia. Our study assesses the frequency and types of ongoing or re-emerging subjective insomnia symptoms and their relationship to subsequent depressive relapse or recurrence in a group of full/partial remitters or recoverers. Method Sixty patients, 18 to 65 years of age, with current MDD defined using DSM-IV-TR criteria were participated in the study. They began a 24-week course of open-label acute plus continuation phase treatment mainly with SSRIs. Maintenance treatment was not planned for not affecting natural relapse or recurrence rates. All participants were evaluated by CGI-S, BDI, HAMD-17, PSQI, and ISI at weeks 0, 4, 12, 24, and 52. Results Majority of the participants (83.33%) had subjective sleep disturbance, insomnia prior to relapse or recurrence. Repeated measures ANOVA was used to evaluate changes in scores of depression and sleep scales over time between recurred (N = 12) and non-recurred groups (N = 48). Differences between means were calculated with post hoc Bonferroni comparison test. The changes in scores of entire clinical scales over time between recurred and non-recurred groups were statistically significant. Limitations The limitations of this study include the use of a relatively small, mostly young female sample and the lack of an objective sleep measure to corroborate self-report scales. Conclusions Early recognition and treatment of disturbances of the sleep–wake cycle may be important for treatment and prevention of recurrence of depression.</description><identifier>ISSN: 0165-0327</identifier><identifier>EISSN: 1573-2517</identifier><identifier>DOI: 10.1016/j.jad.2011.05.056</identifier><identifier>PMID: 21684011</identifier><identifier>CODEN: JADID7</identifier><language>eng</language><publisher>Oxford: Elsevier B.V</publisher><subject>Adult ; Adult and adolescent clinical studies ; Antidepressive Agents - therapeutic use ; Biological and medical sciences ; Depression ; Depressive Disorder, Major - complications ; Depressive Disorder, Major - diagnosis ; Depressive Disorder, Major - drug therapy ; Depressive Disorder, Major - therapy ; Diagnostic and Statistical Manual of Mental Disorders ; Disorders of higher nervous function. Focal brain diseases. Central vestibular syndrome and deafness. Brain stem syndromes ; Female ; Follow-Up Studies ; Humans ; Insomnia ; Male ; Medical sciences ; Mood disorders ; Nervous system (semeiology, syndromes) ; Neurology ; Personality Inventory ; Psychiatric Status Rating Scales ; Psychiatry ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Recurrence ; Relapse ; Remission ; Secondary Prevention ; Serotonin Uptake Inhibitors - therapeutic use ; Sleep ; Sleep Initiation and Maintenance Disorders - complications ; Sleep Initiation and Maintenance Disorders - drug therapy ; Symptoms ; Young Adult</subject><ispartof>Journal of affective disorders, 2011-11, Vol.134 (1), p.257-265</ispartof><rights>Elsevier B.V.</rights><rights>2011 Elsevier B.V.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-651f8570d5da120f5e364b17e0d90303bec2cdca30a358171d49f1e676e6c0e3</citedby><cites>FETCH-LOGICAL-c470t-651f8570d5da120f5e364b17e0d90303bec2cdca30a358171d49f1e676e6c0e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jad.2011.05.056$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27911,27912,30987,45982</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=24570498$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21684011$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gulec, Mustafa</creatorcontrib><creatorcontrib>Selvi, Yavuz</creatorcontrib><creatorcontrib>Boysan, Murat</creatorcontrib><creatorcontrib>Aydin, Adem</creatorcontrib><creatorcontrib>Besiroglu, Lutfullah</creatorcontrib><creatorcontrib>Agargun, Mehmet Yucel</creatorcontrib><title>Ongoing or re-emerging subjective insomnia symptoms after full/partial remission or recovery of major depressive disorder mainly with the selective serotonin reuptake inhibitors and risk of relapse or recurrence: A 52-week follow-up study</title><title>Journal of affective disorders</title><addtitle>J Affect Disord</addtitle><description>Abstract Background Many patients who remit fully/partially or recover from an episode of major depression continue to suffer from sleep problems, mainly insomnia. Our study assesses the frequency and types of ongoing or re-emerging subjective insomnia symptoms and their relationship to subsequent depressive relapse or recurrence in a group of full/partial remitters or recoverers. Method Sixty patients, 18 to 65 years of age, with current MDD defined using DSM-IV-TR criteria were participated in the study. They began a 24-week course of open-label acute plus continuation phase treatment mainly with SSRIs. Maintenance treatment was not planned for not affecting natural relapse or recurrence rates. All participants were evaluated by CGI-S, BDI, HAMD-17, PSQI, and ISI at weeks 0, 4, 12, 24, and 52. Results Majority of the participants (83.33%) had subjective sleep disturbance, insomnia prior to relapse or recurrence. Repeated measures ANOVA was used to evaluate changes in scores of depression and sleep scales over time between recurred (N = 12) and non-recurred groups (N = 48). Differences between means were calculated with post hoc Bonferroni comparison test. The changes in scores of entire clinical scales over time between recurred and non-recurred groups were statistically significant. Limitations The limitations of this study include the use of a relatively small, mostly young female sample and the lack of an objective sleep measure to corroborate self-report scales. Conclusions Early recognition and treatment of disturbances of the sleep–wake cycle may be important for treatment and prevention of recurrence of depression.</description><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Antidepressive Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Depression</subject><subject>Depressive Disorder, Major - complications</subject><subject>Depressive Disorder, Major - diagnosis</subject><subject>Depressive Disorder, Major - drug therapy</subject><subject>Depressive Disorder, Major - therapy</subject><subject>Diagnostic and Statistical Manual of Mental Disorders</subject><subject>Disorders of higher nervous function. Focal brain diseases. Central vestibular syndrome and deafness. Brain stem syndromes</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Insomnia</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mood disorders</subject><subject>Nervous system (semeiology, syndromes)</subject><subject>Neurology</subject><subject>Personality Inventory</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychiatry</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Recurrence</subject><subject>Relapse</subject><subject>Remission</subject><subject>Secondary Prevention</subject><subject>Serotonin Uptake Inhibitors - therapeutic use</subject><subject>Sleep</subject><subject>Sleep Initiation and Maintenance Disorders - complications</subject><subject>Sleep Initiation and Maintenance Disorders - drug therapy</subject><subject>Symptoms</subject><subject>Young Adult</subject><issn>0165-0327</issn><issn>1573-2517</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNp9kl-L1DAUxYso7rr6AXyRvIi-dPambdqOgrAs_oOFfXDfQya5nUknTWqSztAv7WcwZUYFHxYCIe3vnBNObpa9prCiQOvrftULtSqA0hWwtOon2SVlTZkXjDZPs8vEsBzKornIXoTQA0C9buB5dlHQuq2S7DL7dW-3TtstcZ54zHFAv12OYdr0KKM-INE2uMFqQcI8jNENgYguoifdZMz1KHzUwiTtoEPQzp6MpDugn4nryCD69EXh6DH9T3ZKB-dV0g9CWzOTo447EndIAppzYkDvorPaJqdpjGK_XGKnNzo6n9KtIl6H_eLu0Ygx4Dl08h6txA_khrAiPyLuSeeMccd8GkmIk5pfZs86YQK-Ou9X2cOXzw-33_K7-6_fb2_uclk1EPOa0a5lDSimBC2gY1jW1YY2CGoNJZQblIVUUpQgStbShqpq3VGsmxprCVheZe9OtqN3PycMkad2JBojLLop8LZtywrWVZ3I94-S6Z2hgZaxNqH0hErvQvDY8dHrQfg5QQtX856neeDLPHBgaS32b87202ZA9VfxZwAS8PYMiCCF6bywUod_XJVaqNZL-McTh6m1g0bPg9RL2Uqn4iNXTj96jU__qaXRVqfAPc4Yejd5m56DUx4KDvzHMrjL3FIKUNKWlr8BdH_t2w</recordid><startdate>20111101</startdate><enddate>20111101</enddate><creator>Gulec, Mustafa</creator><creator>Selvi, Yavuz</creator><creator>Boysan, Murat</creator><creator>Aydin, Adem</creator><creator>Besiroglu, Lutfullah</creator><creator>Agargun, Mehmet Yucel</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7X8</scope></search><sort><creationdate>20111101</creationdate><title>Ongoing or re-emerging subjective insomnia symptoms after full/partial remission or recovery of major depressive disorder mainly with the selective serotonin reuptake inhibitors and risk of relapse or recurrence: A 52-week follow-up study</title><author>Gulec, Mustafa ; Selvi, Yavuz ; Boysan, Murat ; Aydin, Adem ; Besiroglu, Lutfullah ; Agargun, Mehmet Yucel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-651f8570d5da120f5e364b17e0d90303bec2cdca30a358171d49f1e676e6c0e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Antidepressive Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Depression</topic><topic>Depressive Disorder, Major - complications</topic><topic>Depressive Disorder, Major - diagnosis</topic><topic>Depressive Disorder, Major - drug therapy</topic><topic>Depressive Disorder, Major - therapy</topic><topic>Diagnostic and Statistical Manual of Mental Disorders</topic><topic>Disorders of higher nervous function. Focal brain diseases. Central vestibular syndrome and deafness. Brain stem syndromes</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Insomnia</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mood disorders</topic><topic>Nervous system (semeiology, syndromes)</topic><topic>Neurology</topic><topic>Personality Inventory</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychiatry</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Recurrence</topic><topic>Relapse</topic><topic>Remission</topic><topic>Secondary Prevention</topic><topic>Serotonin Uptake Inhibitors - therapeutic use</topic><topic>Sleep</topic><topic>Sleep Initiation and Maintenance Disorders - complications</topic><topic>Sleep Initiation and Maintenance Disorders - drug therapy</topic><topic>Symptoms</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gulec, Mustafa</creatorcontrib><creatorcontrib>Selvi, Yavuz</creatorcontrib><creatorcontrib>Boysan, Murat</creatorcontrib><creatorcontrib>Aydin, Adem</creatorcontrib><creatorcontrib>Besiroglu, Lutfullah</creatorcontrib><creatorcontrib>Agargun, Mehmet Yucel</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of affective disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gulec, Mustafa</au><au>Selvi, Yavuz</au><au>Boysan, Murat</au><au>Aydin, Adem</au><au>Besiroglu, Lutfullah</au><au>Agargun, Mehmet Yucel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ongoing or re-emerging subjective insomnia symptoms after full/partial remission or recovery of major depressive disorder mainly with the selective serotonin reuptake inhibitors and risk of relapse or recurrence: A 52-week follow-up study</atitle><jtitle>Journal of affective disorders</jtitle><addtitle>J Affect Disord</addtitle><date>2011-11-01</date><risdate>2011</risdate><volume>134</volume><issue>1</issue><spage>257</spage><epage>265</epage><pages>257-265</pages><issn>0165-0327</issn><eissn>1573-2517</eissn><coden>JADID7</coden><abstract>Abstract Background Many patients who remit fully/partially or recover from an episode of major depression continue to suffer from sleep problems, mainly insomnia. Our study assesses the frequency and types of ongoing or re-emerging subjective insomnia symptoms and their relationship to subsequent depressive relapse or recurrence in a group of full/partial remitters or recoverers. Method Sixty patients, 18 to 65 years of age, with current MDD defined using DSM-IV-TR criteria were participated in the study. They began a 24-week course of open-label acute plus continuation phase treatment mainly with SSRIs. Maintenance treatment was not planned for not affecting natural relapse or recurrence rates. All participants were evaluated by CGI-S, BDI, HAMD-17, PSQI, and ISI at weeks 0, 4, 12, 24, and 52. Results Majority of the participants (83.33%) had subjective sleep disturbance, insomnia prior to relapse or recurrence. Repeated measures ANOVA was used to evaluate changes in scores of depression and sleep scales over time between recurred (N = 12) and non-recurred groups (N = 48). Differences between means were calculated with post hoc Bonferroni comparison test. The changes in scores of entire clinical scales over time between recurred and non-recurred groups were statistically significant. Limitations The limitations of this study include the use of a relatively small, mostly young female sample and the lack of an objective sleep measure to corroborate self-report scales. Conclusions Early recognition and treatment of disturbances of the sleep–wake cycle may be important for treatment and prevention of recurrence of depression.</abstract><cop>Oxford</cop><pub>Elsevier B.V</pub><pmid>21684011</pmid><doi>10.1016/j.jad.2011.05.056</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0165-0327
ispartof Journal of affective disorders, 2011-11, Vol.134 (1), p.257-265
issn 0165-0327
1573-2517
language eng
recordid cdi_proquest_miscellaneous_888340946
source MEDLINE; Applied Social Sciences Index & Abstracts (ASSIA); ScienceDirect Journals (5 years ago - present)
subjects Adult
Adult and adolescent clinical studies
Antidepressive Agents - therapeutic use
Biological and medical sciences
Depression
Depressive Disorder, Major - complications
Depressive Disorder, Major - diagnosis
Depressive Disorder, Major - drug therapy
Depressive Disorder, Major - therapy
Diagnostic and Statistical Manual of Mental Disorders
Disorders of higher nervous function. Focal brain diseases. Central vestibular syndrome and deafness. Brain stem syndromes
Female
Follow-Up Studies
Humans
Insomnia
Male
Medical sciences
Mood disorders
Nervous system (semeiology, syndromes)
Neurology
Personality Inventory
Psychiatric Status Rating Scales
Psychiatry
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Recurrence
Relapse
Remission
Secondary Prevention
Serotonin Uptake Inhibitors - therapeutic use
Sleep
Sleep Initiation and Maintenance Disorders - complications
Sleep Initiation and Maintenance Disorders - drug therapy
Symptoms
Young Adult
title Ongoing or re-emerging subjective insomnia symptoms after full/partial remission or recovery of major depressive disorder mainly with the selective serotonin reuptake inhibitors and risk of relapse or recurrence: A 52-week follow-up study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T20%3A31%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ongoing%20or%20re-emerging%20subjective%20insomnia%20symptoms%20after%20full/partial%20remission%20or%20recovery%20of%20major%20depressive%20disorder%20mainly%20with%20the%20selective%20serotonin%20reuptake%20inhibitors%20and%20risk%20of%20relapse%20or%20recurrence:%20A%2052-week%20follow-up%20study&rft.jtitle=Journal%20of%20affective%20disorders&rft.au=Gulec,%20Mustafa&rft.date=2011-11-01&rft.volume=134&rft.issue=1&rft.spage=257&rft.epage=265&rft.pages=257-265&rft.issn=0165-0327&rft.eissn=1573-2517&rft.coden=JADID7&rft_id=info:doi/10.1016/j.jad.2011.05.056&rft_dat=%3Cproquest_cross%3E1010708558%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1010708558&rft_id=info:pmid/21684011&rft_els_id=S0165032711003181&rfr_iscdi=true